Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on modern management of frailty

LIVE: Thursday 17th October 2024, 18:00-19:30 (CEST)

Frailty has a significant impact on health and wellbeing, especially in older adults. Join our experts to understand the factors that contribute to the development of frailty and find out how to manage the condition and reduce the risk of disability, dependency, and mortality.
ADVANCED SEARCH
Log in
Top
Cancer Causes & Control

06-09-2024 | Insomnia Disorders | Original Paper

Sleep and cancer mortality in the Cancer Prevention Study-II

Authors: Sidney M. Donzella, Emily Deubler, Alpa V. Patel, Amanda I. Phipps, Charlie Zhong

Published in: Cancer Causes & Control

Login to get access

Abstract

Purpose

Sleep is a multi-dimensional human function that is associated with cancer outcomes. Previous work on sleep and cancer mortality have not investigated how this relationship varies by sex and cancer site. We investigated the association of sleep duration and perceived insomnia with site-specific and overall cancer mortality among participants in the Cancer Prevention Study–II.

Methods

Sleep was collected at baseline in 1982 among 1.2 million cancer-free US adults. Cancer-specific mortality was determined through 2018. We used multivariable Cox proportional hazard models to calculate hazard ratios and 95% confidence intervals for overall and site-specific cancer mortality, stratified by sex.

Results

Among 983,105 participants (56% female) followed for a median of 27.9 person-years, there were 146,911 primary cancer deaths. Results from the adjusted model showed short (6 h/night) and long (8 h/night and 9–14 h/night) sleep duration, compared to 7 h/night, were associated with a modest 2%, 2%, and 5% higher risk of overall cancer mortality, respectively, and there was a significant non-linear trend (p-trend < 0.01). This non-linear trend was statistically significant among male (p-trend < 0.001) but not female (p-trend 0.71) participants. For male participants, short and long sleep were associated with higher risk of lung cancer mortality and long sleep was associated with higher risk of colorectal cancer mortality. Perceived insomnia was associated with a 3–7% lower risk of overall cancer mortality.

Conclusion

Sleep is important to consider in relation to sex- and site-specific cancer mortality. Future research should investigate other components of sleep in relation to cancer mortality.
Appendix
Available only for authorised users
Literature
1.
Hirshkowitz M, Whiton K, Albert SM et al (2015) National Sleep Foundation’s sleep time duration recommendations: methodology and results summary. Sleep Health 1(1):40–43PubMedCrossRef
2.
Panel CC, Watson NF, Badr MS et al (2015) Recommended amount of sleep for a healthy adult: a joint consensus statement of the American Academy of Sleep Medicine and Sleep Research Society. J Clin Sleep Med 11(6):591–592CrossRef
3.
4.
5.
6.
Stone CR, Haig TR, Fiest KM, McNeil J, Brenner DR, Friedenreich CM (2019) The association between sleep duration and cancer-specific mortality: a systematic review and meta-analysis. Cancer Causes Control 30(5):501–525PubMedCrossRef
7.
Gallicchio L, Kalesan B (2009) Sleep duration and mortality: a systematic review and meta-analysis. J Sleep Res 18(2):148–158PubMedCrossRef
8.
Kripke DF, Garfinkel L, Wingard DL, Klauber MR, Marler MR (2002) Mortality associated with sleep duration and insomnia. Arch Gen Psychiatry 59(2):131–136PubMedCrossRef
9.
Guo X, Zheng L, Wang J et al (2013) Epidemiological evidence for the link between sleep duration and high blood pressure: a systematic review and meta-analysis. Sleep Med 14(4):324–332PubMedCrossRef
10.
Itani O, Jike M, Watanabe N, Kaneita Y (2017) Short sleep duration and health outcomes: a systematic review, meta-analysis, and meta-regression. Sleep Med 32:246–256PubMedCrossRef
11.
Carter BD, Diver WR, Hildebrand JS, Patel AV, Gapstur SM (2014) Circadian disruption and fatal ovarian cancer. Am J Prev Med 46(3):S34–S41PubMedCrossRef
12.
Gapstur SM, Diver WR, Stevens VL, Carter BD, Teras LR, Jacobs EJ (2014) Work schedule, sleep duration, insomnia, and risk of fatal prostate cancer. Am J Prev Med 46(3):S26–S33PubMedCrossRef
13.
Rod NH, Vahtera J, Westerlund H et al (2011) Sleep disturbances and cause-specific mortality: results from the GAZEL cohort study. Am J Epidemiol 173(3):300–309PubMedCrossRef
14.
Sillah A, Watson NF, Peters U et al (2022) Sleep problems and risk of cancer incidence and mortality in an older cohort: the Cardiovascular Health Study (CHS). Cancer Epidemiol 76:102057PubMedCrossRef
15.
Tao F, Cao Z, Jiang Y et al (2021) Associations of sleep duration and quality with incident cardiovascular disease, cancer, and mortality: a prospective cohort study of 407,500 UK biobank participants. Sleep Med 81:401–409PubMedCrossRef
16.
Garfinkel L (1959) Selection, follow-up, and analysis in the American Cancer Society prospective studies1. National Cancer Institute Monograph, p 49
17.
Organization WH (1978) International classification of diseases: [9th] ninth revision, basic tabulation list with alphabetic index. World Health Organization, Geneva
18.
Organization WH (2004) International statistical classification of diseases and related health problems: alphabetical index, vol 3. World Health Organization, Geneva
19.
Jacobs EJ, Newton CC, Wang Y, Campbell PT, Flanders WD, Gapstur SM (2018) Ghost-time bias from imperfect mortality ascertainment in aging cohorts. Ann Epidemiol 28(10):691–696. e3PubMedCrossRef
20.
Cai H, Shu X-O, Xiang Y-B et al (2015) Sleep duration and mortality: a prospective study of 113,138 middle-aged and elderly Chinese men and women. Sleep 38(4):529–536PubMedPubMedCentralCrossRef
21.
Åkerstedt T, Bellocco R, Widman L et al (2023) The association of short and long sleep with mortality in men and women. J Sleep Res 33:e13931PubMedCrossRef
22.
23.
24.
Irwin MR, Carrillo C, Olmstead R (2010) Sleep loss activates cellular markers of inflammation: sex differences. Brain Behav Immun 24(1):54–57PubMedCrossRef
25.
Prather AA, Vogelzangs N, Penninx BW (2015) Sleep duration, insomnia, and markers of systemic inflammation: results from the Netherlands Study of Depression and Anxiety (NESDA). J Psychiatr Res 60:95–102PubMedCrossRef
26.
Irwin MR, Olmstead R, Carroll JE (2016) Sleep disturbance, sleep duration, and inflammation: a systematic review and meta-analysis of cohort studies and experimental sleep deprivation. Biol Psychiatry 80(1):40–52PubMedCrossRef
27.
Singh-Manoux A, Shipley MJ, Bell JA, Canonico M, Elbaz A, Kivimäki M (2017) Association between inflammatory biomarkers and all-cause, cardiovascular and cancer-related mortality. Cand Med Assoc J 189(10):E384–E390CrossRef
28.
Wong JY, Bassig BA, Vermeulen R et al (2017) Sleep duration across the adult lifecourse and risk of lung cancer mortality: a cohort study in Xuanwei, China. Cancer Prev Res 10(6):327–336CrossRef
29.
Jaehne A, Unbehaun T, Feige B, Lutz UC, Batra A, Riemann D (2012) How smoking affects sleep: a polysomnographical analysis. Sleep Med 13(10):1286–1292PubMedCrossRef
30.
Shopland DR (1995) Tobacco use and its contribution to early cancer mortality with a special emphasis on cigarette smoking. Environ Health Perspect 103(suppl 8):131–142PubMedPubMedCentralCrossRef
31.
Zhang L, Samet J, Caffo B, Punjabi NM (2006) Cigarette smoking and nocturnal sleep architecture. Am J Epidemiol 164(6):529–537PubMedCrossRef
32.
Marinac CR, Nelson SH, Flatt SW, Natarajan L, Pierce JP, Patterson RE (2017) Sleep duration and breast cancer prognosis: perspectives from the Women’s Healthy Eating and Living Study. Breast Cancer Res Treat 162:581–589PubMedPubMedCentralCrossRef
33.
Wu T, Zou Y, Xu K et al (2023) Insomnia and multiple health outcomes: umbrella review of meta-analyses of prospective cohort studies. Public Health 215:66–74PubMedCrossRef
34.
Hakim F, Wang Y, Zhang SX et al (2014) Fragmented sleep accelerates tumor growth and progression through recruitment of tumor-associated macrophages and TLR4 signaling disrupted sleep and cancer. Cancer Res 74(5):1329–1337PubMedPubMedCentralCrossRef
35.
Parthasarathy S, Vasquez MM, Halonen M et al (2015) Persistent insomnia is associated with mortality risk. Am J Med 128(3):268–275. e2PubMedCrossRef
36.
37.
38.
Jiao L, Duan Z, Sangi-Haghpeykar H, Hale L, White D, El-Serag H (2013) Sleep duration and incidence of colorectal cancer in postmenopausal women. Br J Cancer 108(1):213–221PubMedPubMedCentralCrossRef
39.
40.
Hu L, Harper A, Heer E et al (2020) Social jetlag and prostate cancer incidence in Alberta’s Tomorrow Project: a prospective cohort study. Cancers 12(12):3873PubMedPubMedCentralCrossRef
41.
McNeil J, Barberio AM, Friedenreich CM, Brenner DR (2019) Sleep and cancer incidence in Alberta’s Tomorrow Project cohort. Sleep 42(3):zsy252PubMedCrossRef
42.
Dillon HR, Lichstein KL, Dautovich ND, Taylor DJ, Riedel BW, Bush AJ (2015) Variability in self-reported normal sleep across the adult age span. J Gerontol B 70(1):46–56CrossRef
43.
Kocevska D, Lysen TS, Dotinga A et al (2021) Sleep characteristics across the lifespan in 1.1 million people from the Netherlands, United Kingdom and United States: a systematic review and meta-analysis. Nat Hum Behav 5(1):113–122PubMedCrossRef
44.
45.
Evans MA, Buysse DJ, Marsland AL et al (2021) Meta-analysis of age and actigraphy-assessed sleep characteristics across the lifespan. Sleep 44(9):zsab088PubMedPubMedCentralCrossRef
46.
Roenneberg T, Wirz-Justice A, Merrow M (2003) Life between clocks: daily temporal patterns of human chronotypes. J Biol Rhythms 18(1):80–90PubMedCrossRef
47.
48.
Thorleifsdottir B, Björnsson J, Benediktsdottir B, Gislason T, Kristbjarnarson H (2002) Sleep and sleep habits from childhood to young adulthood over a 10-year period. J Psychosom Res 53(1):529–537PubMedCrossRef
49.
Zeitlhofer J, Schmeiser-Rieder A, Tribl G et al (2000) Sleep and quality of life in the Austrian population. Acta Neurol Scand 102(4):249–257PubMedCrossRef
50.
51.
Satin JR, Linden W, Phillips MJ (2009) Depression as a predictor of disease progression and mortality in cancer patients: a meta-analysis. Cancer 115(22):5349–5361PubMedCrossRef
52.
Luojus MK, Lehto SM, Tolmunen T, Erkkilä AT, Kauhanen J (2014) Sleep duration and incidence of lung cancer in ageing men. BMC Public Health 14(1):1–7CrossRef
53.
Pinheiro SP, Schernhammer ES, Tworoger SS, Michels KB (2006) A prospective study on habitual duration of sleep and incidence of breast cancer in a large cohort of women. Cancer Res 66(10):5521–5525PubMedCrossRef
54.
Palesh O, Aldridge-Gerry A, Zeitzer JM et al (2014) Actigraphy-measured sleep disruption as a predictor of survival among women with advanced breast cancer. Sleep 37(5):837–842PubMedPubMedCentralCrossRef
Metadata
Title
Sleep and cancer mortality in the Cancer Prevention Study-II
Authors
Sidney M. Donzella
Emily Deubler
Alpa V. Patel
Amanda I. Phipps
Charlie Zhong
Publication date
06-09-2024
Publisher
Springer International Publishing
Published in
Cancer Causes & Control
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-024-01910-3

2024 ESMO Congress

Add-on Ra223 could be a new first-line option in mCRPC

Adding radium-223 to first-line enzalutamide significantly improves the survival of patients with bone metastatic castration-resistant prostate cancer.

Read more

AI model can predict tumor mutations

No OS benefit of adding preoperative CRT in gastric cancer

T-DXd supported for breast cancer with brain metastases

» View more highlights on the ESMO 2024 hub page

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

  • Webinar | 01-10-2024 | 12:30 (CEST)

Live event concluded

In this webinar, Professor Martin Dreyling and an esteemed, international panel of CAR-T experts discuss the latest data on the safety, efficacy, and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL.

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by: Novartis Pharma AG

Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare
Get a reminder for the on-demand version
Image Credits